Knee surgeries and arthroplasty pain management therapeutics market

Knee Surgeries and Arthroplasty Pain Management Therapeutics Market, by Drug (Acetaminophen, COX-2 inhibitors, Opioids, Non-steroidal Anti-inflammatories, Ketamine, and Others ), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Apr 2022
CMI4998
177 Pages
Excel & Pdf
Pharmaceutical

Summary

Surge in the number of knee surgeries and arthroplasty and rising awareness about knee surgeries and arthroplasty is expected to drive growth of the knee surgeries and arthroplasty pain management therapeutics market during the forecast period

For instance, in October 2018, Apollo Hospitals, Aragonda conducted a Walkathon event with the main objective of promoting walking for pain free knees. The purpose of the event was to raise awareness about arthritis and how to overcome it with the World Arthritis Day theme. The Apollo Hospitals introduced Total Knee Replacement (TKR) surgeries at its Aragonda unit and since then, as many as 65 surgeries had been done at an affordable cost. Apollo Hospitals, Aragonda created awareness among people about the importance of total knee replacement (TKR) surgeries.

The global knee surgeries and arthroplasty pain management therapeutics market is estimated to be valued at US$ 4,211.7 million in 2022 and expected to exhibit a CAGR of 4.8% over the forecast period (2022-2030).

Figure 1. Global Knee Surgeries and Arthroplasty Pain Management Therapeutics Market Share (%) in Terms of Value, By Region, 2022

Key players operating in the market are focusing on the development and approval of novel therapeutics for the treatment of knee surgeries and arthroplasty pain, which is expected to offer a lucrative opportunity for market players to launch innovative products in the market

For instance, in December 2021, Heron Therapeutics, Inc., a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that the U.S. Food and Drug Administration (FDA) had approved its supplemental New Drug Application (sNDA) for ZYNRELEF (bupivacaine and meloxicam) extended-release solution to significantly expand the indication. ZYNRELEF is now indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Knee Surgeries and Arthroplasty Pain Management Therapeutics Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 4,211.7 Mn
Historical Data for:	2017 to 2021	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	4.8%	2030 Value Projection:	US$ 6,127.5 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug: Acetaminophen, COX-2 inhibitors, Opioids, Non-steroidal Anti-inflammatories, Ketamine, Others By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:	Pfizer Inc, Allay Therapeutics, Mallinckrodt, Johnson & Johnson, Zydus Cadila Healthcare Ltd., Novartis AG, Purdue Pharma, Delphis Pharmaceutical, Taj Pharmaceuticals Limited, GlaxoSmithKline plc, AbbVie Inc., and Aurobindo Pharma
Growth Drivers:	Surge in the number of knee surgeries and arthroplasty Increasing research and development activities by pharmaceutical companies
Restraints & Challenges:	Product recall Side effects associated with the use of medication

Figure 2. Global Knee Surgeries and Arthroplasty Pain Management Therapeutics Market Share (%), by Distribution Channel, 2022

Global Knee Surgeries and Arthroplasty Pain Management Therapeutics Market: Restraint

The growth of the global knee surgeries and arthroplasty pain management therapeutics market may be hampered, owing to product recalls and side effects associated with the use of medication

For instance, in April 2021, A-S Medication Solutions, LLC (ASM), formerly Allscripts Medication Services Group (founded in 1988) – the industry leader in providing complete, end-to-end turnkey, on-site medication dispensing solutions, voluntarily recalled 198,350 bottles of Acetaminophen Extra Strength 500 mg Tablets, 100 ct. bottles contained in Health Essentials Kits distributed by Humana, a for-profit American health insurance company, to its members. This recall was conducted to the consumer level. These over-the-counter (OTC) analgesic products contain an incomplete prescription drug label rather than the required over-the-counter (OTC) drug facts label.

Moreover, some common side effects of COX-2 inhibitors include abdominal pain, headache, nausea, diarrhea, flatulence, and insomnia. COX-2 inhibitors and other Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of heart attacks, stroke, and related conditions, which can be fatal. This risk may increase with the duration of use in patients who have underlying risk factors for disease of the heart and blood vessels.

Key Players

Major players operating in the global knee surgeries and arthroplasty pain management therapeutics market include Pfizer Inc, Allay Therapeutics, Mallinckrodt, Johnson & Johnson, Zydus Cadila Healthcare Ltd., Novartis AG, Purdue Pharma, Delphis Pharmaceutical, Taj Pharmaceuticals Limited, GlaxoSmithKline plc, AbbVie Inc., and Aurobindo Pharma

Table of Content

Table of Contents

*Browse 27 market data tables and 30 figures on "Global Knee Surgeries and Arthroplasty Pain Management Therapeutics Market” - forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global knee surgeries and arthroplasty pain management therapeutics market during the forecast period (2022-2030)?

The global knee surgeries and arthroplasty pain management therapeutics market size is estimated to be valued at US$ 4,211.7 Mn in 2022 and expected to exhibit a CAGR of 4.8% between 2022 and 2030.

What are the major factors driving the market growth?

Surge in the number of knee surgeries and arthroplasty and increasing research and development activities by pharmaceutical companies is expected to drive the market growth over the forecast period.

Which is the leading drug in the market?

Non-steroidal Anti-inflammatories segment is expected to hold the major market share in the market.

Which region holds the largest market share in the market?

North America holds the largest market share in the market.

What are the key factors hampering the growth of the market?

Major factors hampering the market growth include product recall and side effects associated with the use of medication.

Which are the major players operating in the market?

Major players operating in the market include Pfizer Inc, Allay Therapeutics, Mallinckrodt, Johnson & Johnson, Zydus Cadila Healthcare Ltd., Novartis AG, Purdue Pharma, Delphis Pharmaceutical, Taj Pharmaceuticals Limited, GlaxoSmithKline plc, AbbVie Inc., and Aurobindo Pharma.